Zobrazeno 1 - 10
of 73
pro vyhledávání: '"rapid-onset opioids"'
Autor:
Yi-Hao Chiang, Ching-Ting Lien, Wen-Hao Su, Tsung-Yu Yen, Yu-Jen Chen, Yuen-Liang Lai, Ken-Hong Lim, Kun-Yao Dai, Hsin-Pei Chung, Chia-Yen Hung, Yi-Shing Leu
Publikováno v:
BMC Palliative Care, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Background Clinical evidence for the rapidity and effectiveness of fentanyl buccal soluble film (FBSF) in reducing pain intensity of breakthrough cancer pain (BTcP) remains inadequate. This study aimed to evaluate the efficacy of FBSF propor
Externí odkaz:
https://doaj.org/article/990397aded314904b25b731d8795187e
Autor:
Jinseok Yeo
Publikováno v:
Journal of Yeungnam Medical Science, Vol 41, Iss 1, Pp 22-29 (2024)
Breakthrough pain is transitory pain that occurs despite the use of opioids for background pain control. Breakthrough pain occurs in 40% to 80% of patients with cancer pain. Despite effective analgesic therapy, patients and their caregivers often fee
Externí odkaz:
https://doaj.org/article/396cd11ceccb495daea4cef524bdea97
Autor:
Paolo Bossi, Tatiana Pietrzyńska, César Margarit Ferri, Irene Mansilla, Valeria Tellone, Sara Fioravanti, Giorgio Di Loreto, Alessandro Comandini
Publikováno v:
Frontiers in Pain Research, Vol 5 (2024)
IntroductionThis study aimed to assess the percentage of patients treated according to the European Society for Medical Oncology (ESMO) 2018 guidelines for breakthrough cancer pain (BTcP) and the impact of guidelines adherence on patients' quality of
Externí odkaz:
https://doaj.org/article/0379b3310cb64cfab162bebbcd76b3e8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Open Medicine, Vol 17, Iss 1, Pp 34-45 (2021)
Chronic pain and breakthrough cancer pain (BTcP) have a high prevalence in all cancer types and cancer stages, combined with a significant physical, psychological, and economic burden. Despite efforts to improve appropriate management of cancer pain,
Externí odkaz:
https://doaj.org/article/c5e2398abad04d03b96a4e4ec741c66c
Publikováno v:
Frontiers in Pain Research, Vol 3 (2022)
Background and ObjectiveRapid-onset opioids (ROOs) are effective treatments for breakthrough cancer pain (BTcP) given their rapid onset of action and relatively short duration of analgesia. The aim of this article is to describe specific consideratio
Externí odkaz:
https://doaj.org/article/a196f92f784f44039073162e7119bc24
Autor:
Camps Herrero C, Antón Torres A, Cruz-Hernández JJ, Carrato A, Constenla M, Díaz-Rubio E, Feyjoo Saus M, Garcia-Foncillas J, Gascón P, Guillem V
Publikováno v:
Journal of Pain Research, Vol Volume 12, Pp 2349-2358 (2019)
Carlos Camps Herrero,1 Antonio Antón Torres,2 Juan Jesús Cruz-Hernández,3 Alfredo Carrato,4 Manuel Constenla,5 Eduardo Díaz-Rubio,6 Margarita Feyjoo Saus,7 Jesus Garcia-Foncillas,8 Pere Gascón,9 Vicente Guillem101Jefe de Servicio de Oncología M
Externí odkaz:
https://doaj.org/article/f29c34a74af3471d86758efe8a018135
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Open Medicine
Open Medicine, Vol 17, Iss 1, Pp 34-45 (2021)
Open Medicine, Vol 17, Iss 1, Pp 34-45 (2021)
Introduction Chronic pain and breakthrough cancer pain (BTcP) have a high prevalence in all cancer types and cancer stages, combined with a significant physical, psychological, and economic burden. Despite efforts to improve appropriate management of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c430bbf1b5ae607cae3379f9ee220e6f
http://europepmc.org/articles/PMC8651060
http://europepmc.org/articles/PMC8651060
Autor:
Marco Cascella, Federica Monaco, Davide Nocerino, Elisabetta Chinè, Roberta Carpenedo, Paola Picerno, Laura Migliaccio, Angela Armignacco, Giulia Franceschini, Sergio Coluccia, Piergiacomo Di Gennaro, Maura C Tracey, Cira A Forte, Mariangela Tafuri, Anna Crispo, Francesco Cutugno, Alessandro Vittori, Silvia Natoli, Arturo Cuomo
Proper breakthrough cancer pain (BTcP) management is of pivotal importance. Although rapid-acting, oral and nasal transmucosal, fentanyl formulations (rapid-onset opioids, ROOs) are licensed for BTcP treatment, not all guidelines recommend their use.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2ba864ae8669751d44a82e2231b5f08
https://hdl.handle.net/2108/311296
https://hdl.handle.net/2108/311296
